Aurelio Bonavia | Vaccine Development
Bill & Melinda Gates Medical Research Institute

Dr. Aurelio Bonavia works in Vaccine Development at the Gates Medical Research Institute developing adjuvants/vaccines/monoclonals for Malaria, Shigella, and RSV.  Previously he served as Sr. Director of Clinical Development at Vir Biotechnology where he was the Study Director for VIR-2482 a monoclonal antibody for the prophylaxis of influenza A.   Aurelio also spearheaded the development of the CMV-vectored HIV and TB prophylactic vaccines and a monoclonal antibody against RSV/MPV. Dr. Bonavia previously worked at Functional Genetics, Novartis, Theraclone Sciences, and Aeras.  He has led discovery, translational and clinical programs in Flu, RSV, HMPV, PIV, HIV, TB, CMV, Ebola, and adjuvants. He received his PhD from the University of Colorado Health Sciences Center for his work in Human Coronavirus 229E receptor mapping, carried his postdoctoral work in SIV/HIV at Johns Hopkins Medical School and was a Research Fellow at NIH-NIAID-LVD working on HCoV-SARS-1.